Axentis Pharma AG

axentispharma.com

Axentis Pharma AG is a Swiss-based pharmaceutical company focused on value-added anti-infectives in combination with novel inhalation devices. Following the entrance of a License Agreement with a Japanese partner, Axentis Pharma engaged in the development of AX-TOBRA, a liposome-based drug-device combination to combat chronic lung diseases and respiratory disorders, especially cystic fibrosis. AX-TOBRA received Orphan Designations from EU-EMA and US-FDA. To protect Axentis Pharma against loss and damage from malversations caused by its Japanese partner, Axentis Pharma initiated arbitration proceedings in Tokyo, and, ultimately, won a final and binding Arbitration Award against its former partner. The award was issued by the Japan Commercial Arbitration Association (JCAA) in Tokyo in August 2013. Currently, Axentis Pharma is seeking to enforce the Arbitration Award through judicial remedies.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

MODERNA, ASTRAZENECA AND J&J CORONAVIRUS SHOTS REV UP FOR NIH TESTS BEGINNING IN JULY: WSJ

Fiercepharma | June 10, 2020

news image

As leading coronavirus vaccines make their way through early stages of human testing, the NIH is plotting much larger efficacy studies this summer. U.S. researchers plan to run phase 3 trials of vaccines from Moderna, AstraZeneca and Johnson & Johnson in the coming months, the Wall Street Journal reports. The NIH intends to start a phase 3 trial of Moderna’s vaccine in July, followed by an August trial of AstraZeneca’s vaccine and a September study of Johnson & Johnson&...

Read More

BUSINESS INSIGHTS

NANOPASS AND M2N ENTER STRATEGIC DEVELOPMENT & FOUNDRY AGREEMENT

NanoPass; M2N | December 23, 2021

news image

NanoPass Technologies and Micro2Nano have reached an agreement to enter a strategic development and production relationship for the design and production of NanoPass's proprietary MEMS based microneedles. The aim of the collaboration is to strengthen the relationship between NanoPass and M2N and provide a basis for the continued growth of the two comaim of the collaboration is to strengthen the relationship between NanoPass and M2N panies while basing the new agreement on year...

Read More

PHARMA TECH

IXENSOR RECEIVES STRATEGIC INVESTMENT FROM ROHTO PHARMACEUTICAL WITH A SEPARATE TECHNOLOGY LICENSING AGREEMENT

iXensor | April 28, 2022

news image

iXensor, the pioneer of mobile health, announced that Rohto Pharmaceutical Co., Ltd, a multinational pharmaceutical corporation headquartered in Japan, has become the new strategic partner and shareholder. iXensor received Rohto Pharmaceutical's strategic investment to expand its mobile health business globally and accelerate its PixoTech® platform licensing business. Building on this strategic partnership, Rohto Pharmaceutical will deploy iXensor's patented PixoTech&r...

Read More

PHARMA TITANS TEAM TO TACKLE COVID-19

Precision Vaccinations | April 14, 2020

news image

Considering the extraordinary humanitarian challenge of ending the ongoing coronavirus pandemic, two leading pharmaceutical companies believe establishing a collaboration is the best tactic for bringing a world-class vaccine. Announced in a joint press release on April 14, 2020, GSK and Sanofi said the ‘global access to COVID-19 vaccines is a priority and are committed to making any vaccine that is developed through the collaboration affordable to the public.’ ‘And through mech...

Read More
news image

MODERNA, ASTRAZENECA AND J&J CORONAVIRUS SHOTS REV UP FOR NIH TESTS BEGINNING IN JULY: WSJ

Fiercepharma | June 10, 2020

As leading coronavirus vaccines make their way through early stages of human testing, the NIH is plotting much larger efficacy studies this summer. U.S. researchers plan to run phase 3 trials of vaccines from Moderna, AstraZeneca and Johnson & Johnson in the coming months, the Wall Street Journal reports. The NIH intends to start a phase 3 trial of Moderna’s vaccine in July, followed by an August trial of AstraZeneca’s vaccine and a September study of Johnson & Johnson&...

Read More
news image

BUSINESS INSIGHTS

NANOPASS AND M2N ENTER STRATEGIC DEVELOPMENT & FOUNDRY AGREEMENT

NanoPass; M2N | December 23, 2021

NanoPass Technologies and Micro2Nano have reached an agreement to enter a strategic development and production relationship for the design and production of NanoPass's proprietary MEMS based microneedles. The aim of the collaboration is to strengthen the relationship between NanoPass and M2N and provide a basis for the continued growth of the two comaim of the collaboration is to strengthen the relationship between NanoPass and M2N panies while basing the new agreement on year...

Read More
news image

PHARMA TECH

IXENSOR RECEIVES STRATEGIC INVESTMENT FROM ROHTO PHARMACEUTICAL WITH A SEPARATE TECHNOLOGY LICENSING AGREEMENT

iXensor | April 28, 2022

iXensor, the pioneer of mobile health, announced that Rohto Pharmaceutical Co., Ltd, a multinational pharmaceutical corporation headquartered in Japan, has become the new strategic partner and shareholder. iXensor received Rohto Pharmaceutical's strategic investment to expand its mobile health business globally and accelerate its PixoTech® platform licensing business. Building on this strategic partnership, Rohto Pharmaceutical will deploy iXensor's patented PixoTech&r...

Read More
news image

PHARMA TITANS TEAM TO TACKLE COVID-19

Precision Vaccinations | April 14, 2020

Considering the extraordinary humanitarian challenge of ending the ongoing coronavirus pandemic, two leading pharmaceutical companies believe establishing a collaboration is the best tactic for bringing a world-class vaccine. Announced in a joint press release on April 14, 2020, GSK and Sanofi said the ‘global access to COVID-19 vaccines is a priority and are committed to making any vaccine that is developed through the collaboration affordable to the public.’ ‘And through mech...

Read More